# Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy

> **NCT03948477** · PHASE2 · COMPLETED · sponsor: **University of Auckland, New Zealand** · enrollment: 160 (actual)

## Conditions studied

- Oncology
- Breast Cancer
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Pantoprazole 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03948477
- **Lead sponsor:** University of Auckland, New Zealand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2021-10-15
- **Final completion:** 2021-10-15
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948477, "Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03948477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*